MGNX News and Press, MacroGenics Inc. From 12/19/19

ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a...

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright. More news on: Aimmune Therapeutics, Inc., Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

MacroGenics ( MGNX -2.9% ) is down on double normal volume in response to results from a second interim survival analysis of Phase 3 clinical trial, SOPHIA , comparing lead drug margetuximab + chemo to Roche's Herceptin (trastuzumab) + chemo in patients with HER2-positive metastatic bre...

Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phas...

Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management...

After a key investment research firm on Wall Street issued a discouraging assessment for its most advanced clinical drug program, MacroGenics (NASDAQ: MGNX)  saw its shares lose over 10% of their value in early trading before bouncing back to a 7.5% drop at 11:30 a.m. EST on Thursday. M...

MacroGenics (NASDAQ: MGNX ) sinks 6.1%  in premarket trading after Morgan Stanley analyst David Lebowitz cuts his rating to underweight from equal-weight. More news on: MacroGenics, Inc., Healthcare stocks news, Stocks on the move, Read more ...